Skip to Content
Merck
All Photos(1)

Documents

T0040800

Tenoxicam

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C13H11N3O4S2
CAS Number:
59804-37-4
Molecular Weight:
337.37
MDL number:
MFCD00083502
UNSPSC Code:
41116107
PubChem Substance ID:
329826581
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

tenoxicam

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C(NC1=NC=CC=C1)C2=C(O)C(SC=C3)=C3S(N2C)(=O)=O

InChI

1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,17H,1H3,(H,14,15,18)

InChI key

LZNWYQJJBLGYLT-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Tenoxicam EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Non-steroidal antiinflammatory drug (NSAID) with comparatively low risk of renal or hepatic toxicity.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301 + H311 + H331

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

D Ulusoy Karatopuk et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 21(2), 146-152 (2010-09-28)
Tenoxicam is a non-steroidal antiinflammatory drug, which has antipyretic and antiinflammatory effects. Though it is known that the major side effect of non-steroidal antiinflammatory drugs is on the gastrointestinal tract and liver, there have been few studies regarding the effects
Michael H Bennett et al.
Anesthesia and analgesia, 111(3), 757-762 (2010-03-25)
Decompression illness (DCI) is caused by bubble formation in the blood or tissues after a reduction in ambient pressure. Clinically, DCI may range from a trivial illness to paralysis, loss of consciousness, cardiovascular collapse, and death. Recompression is the universally
Ebru Cubuk Demiralay et al.
Journal of separation science, 32(17), 2928-2936 (2009-08-08)
In this study, pK(a) values were determined by using the dependence of the capacity factor on the pH of the mobile phase for four ionizable substances, namely, tenoxicam, piroxicam, meloxicam, and naproxen (I.S.). The effect of the mobile phase composition
Michael H Bennett et al.
The Cochrane database of systematic reviews, 5(5), CD005277-CD005277 (2012-05-18)
Decompression illness (DCI) is due to bubble formation in the blood or tissues following the breathing of compressed gas. Clinically, DCI may range from a trivial illness to loss of consciousness, death or paralysis. Recompression is the universally accepted standard
I Aktas et al.
International journal of oral and maxillofacial surgery, 39(5), 440-445 (2010-03-10)
This study examined the clinical and radiological effects of intra-articular tenoxicam injection following arthrocentesis and compared them with arthrocentesis alone in patients with disc displacement without reduction (DDwoR). 24 temporomandibular joints (TMJs) in 21 patients with DDwoR were studied. Patients
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service